ADMA Biologics, Inc. (ADMA)
- Previous Close
6.54 - Open
6.54 - Bid 6.41 x 300
- Ask 6.52 x 300
- Day's Range
6.42 - 6.55 - 52 Week Range
3.06 - 6.76 - Volume
1,663,464 - Avg. Volume
2,528,832 - Market Cap (intraday)
1.497B - Beta (5Y Monthly) 0.43
- PE Ratio (TTM)
-- - EPS (TTM)
-0.13 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.38
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
www.admabiologics.comRecent News: ADMA
Performance Overview: ADMA
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADMA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADMA
Valuation Measures
Market Cap
1.50B
Enterprise Value
1.59B
Trailing P/E
--
Forward P/E
22.27
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.60
Price/Book (mrq)
11.07
Enterprise Value/Revenue
6.15
Enterprise Value/EBITDA
310.02
Financial Highlights
Profitability and Income Statement
Profit Margin
-10.94%
Return on Assets (ttm)
4.51%
Return on Equity (ttm)
-19.67%
Revenue (ttm)
258.22M
Net Income Avi to Common (ttm)
-28.24M
Diluted EPS (ttm)
-0.13
Balance Sheet and Cash Flow
Total Cash (mrq)
51.35M
Total Debt/Equity (mrq)
104.59%
Levered Free Cash Flow (ttm)
378.12k